Patient characteristics
NASH disease, PCOS,, SBP, systolic blood pressure, NASH, polycystic ovarian syndrome
DISEASE, LIVER FIBROSIS
From June 2021 through January 2022, 51 patients were approached for this study, 40 (78%) of whom were enrolled (Fig. Trial CONSORT Diagram.The mean age of the study participants was 52±13 years (range 24–74 y) and 75% (n=30) were female. The majority of participants were Caucasian (n=38) and 43% (n=17) had a college degree. The mean baseline body mass index (BMI) was 35.5 kg/mFor NASH disease staging, 40% (n=16) of the patients had a historical liver biopsy. The other 60% (n=24) had noninvasive disease assessment. In aggregate, individual liver fibrosis stages were as follows: stage F0/F1 (n=17, 43%), stage F2 (n=20, 40%), and stage F3 (n=3, 17%). At baseline, 40% (n=16) of subjects were on stable doses of drug therapies for NASH, including 9 who were taking Vitamin E, 5 receiving a glucagon-like peptide (GLP-1) agonist (semaglutide n=4, liraglutide n=1), and 2 who were prescribed pioglitazone.There were no significant differences in baseline demographic or clinical characteristics between the NW and standard clinical care groups (Table Baseline comparisons between Noom Weight and Standard Clinical Care participantsNote: Randomization worked well as there were no clinically significant differences between the NW group and the standard of care control.Continuous variables reported as mean±SD **2-sample Abbreviations: ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker; BB, beta blocker; CCB, calcium channel blocker; DBP, diastolic blood pressure; GLP, glucagon-like peptide; HS, high school; PCOS, polycystic ovarian syndrome; SBP, systolic blood pressure; SGLT, sodium-glucose transport protein.